Pay in 4 interest-free payments of $5.40 Learn more
Ships within 48 hours · Estimated delivery Oct 10 - Oct 15
no aspiration) Subcutaneous Drug Injection Review (PMC) Pharmacologic considerations of the subcutaneous route Additional Research and Background These sources provide related context and are not presented as support for a specific statement above
Andrea Corona MapLight reports mixed results in Schizophrenia trial In their Phase 2 ZEPHR trial, MapLights novel oral drug for schizophrenia, the Ml/M4 muscarinic agonist ML-007C-MA, successfully hit its primary endpoint but only for the twice-daily version, not the once-daily dose
It was previously available through compounding pharmacies as a bulk drug substance, but the FDA reclassified it as a Category 2 substance, which effectively restricts compounding pharmacies from producing it
Each vial contains either 10mg or 20mg, requiring reconstitution for effective use
Delivery timelines, payment methods, and international shipping availability follow the policies described on our shipping and payments page, please note that shipping depends on current laws and logistical environment
US$ 26.24
US$ 25.05
US$ 28.10
US$ 20.26
US$ 20.73
US$ 26.83
US$ 29.44
